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Cytogenetic and molecular studies have suggested that deletion or rearrangement of sequences that map to the short arm of
chromosome 8 may be permissive for tumorigenesis in several organ systems, and in human prostate tumors in particular. In
this study, we hypothesized that genes deleted for one copy and localized to the 8p chromosomal region may be
transcriptionally down-regulated or ablated in affected human prostate tumor tissues. To test this hypothesis, we used cDNA
microarray analysis to determine the transcriptional profiles for 259 transcribed sequences mapping to the 8p chromosomal
region for seven human prostate tumor xenografts, completely characterized for numerical and structural alterations on
chromosome 8, and five normal human prostate tissues. These experiments identified 33 genes differentially expressed
between normal and malignant prostate tissues, the majority of which (28/33, 85%) were transcriptionally down-regulated in
malignant compared to normal human prostate tissues. These findings, that haploinsufficiency and transcriptional down-
regulation for genes mapping to 8p are largely coincident in human prostate tumors, should provide a powerful tool for the
identification of tumor-suppressor genes associated with human prostate cancer initiation and progression.
© 2003 Wiley-Liss, Inc.
INTRODUCTION
Cytogenetic and molecular studies have sug-
gested that deletion or rearrangement of sequences
that map to the short arm of chromosome 8 may be
permissive for tumorigenesis in several organ sys-
tems. In prostate carcinoma, early work by Berger-
heim et al. (1993) by the use of Southern blot
techniques showed high frequencies of deletion of
distal 8p sequences in human prostate tumors, and
suggested that a breakpoint existed between the
NEFL locus at 8p21 and the PLAT locus at 8p21–
8p11. Subsequent work in our laboratory identified
a major region of deletion mapping to 8p22 in
human prostate cancer (Macoska et al., 1995). This
was corroborated by the description and later char-
acterization of a homozygous deletion within the
8p22–p23 region in a prostate tumor (Bova et al.,
1993, 1996). The use of polymerase chain reaction
(PCR) and fluorescence in situ hybridization
(FISH) techniques in our laboratory and by others
confirmed frequent loss of distal 8p sequences and
showed that this region of deletion could be quite
extensive, including the entire 8p chromosome arm
or large portions of 8p extending from 8pter to
8p11–12 (MacGrogan et al., 1994; Macoska et al.,
1994; Trapman et al., 1994; Prasad et al., 1998).
Two large studies from our laboratory showed in-
terstitial deletions of distal sequences mapping to
8p22, 8p21, and 8p11–p12, including homozygous
deletion of sequences mapping to the D8S87 locus
at 8p12, in human prostate tumors (Macoska et al.,
1995; Prasad et al., 1998). As a result of these
studies, we and others have hypothesized that one
or more tumor-suppressor genes critical for prostate
tumorigenesis map to 8p.
It is reasonable to propose that the transcription
of genes mapping to chromosomal regions deleted
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for one or both copies may be down-regulated or
ablated in the affected tumor tissues. If so, then
deletion-induced haploinsufficiency alone may re-
sult in reduced or ablated gene transcription in
affected tumor tissues. To test this hypothesis, we
determined the RNA profiles of seven human pros-
tate tumor xenografts, completely characterized for
numerical and structural alterations on chromo-
some 8, and five normal human prostate tissues for
677 transcribed sequences mapping to chromo-
some 8, by use of cDNA microarray analysis. These
experiments demonstrate the down-regulation or
ablation of transcripts from 28 genes mapping to
regions of 8p deleted in the prostate tumor xeno-
grafts and are consistent with the identification of
these sequences as candidate tumor-suppressor
genes that are inactivated during prostate tumori-
genesis.
MATERIALS AND METHODS
Tissue Acquisition and Characterization
Normal benign human prostate tissue was ob-
tained after radical prostatectomy from patients di-
agnosed with prostate cancer. After an initial patho-
logic evaluation of radical prostatectomy tissue,
presumed normal tissue was snap-frozen in liquid
nitrogen and stored at 70°C. One section from
each specimen was examined after staining with
H&E, and the specimen was included in the study
if the section demonstrated at least 70% epithelial
cells. All radical prostatectomy specimens were ac-
quired with full Institutional Review Board ap-
proval. The LuCaP series of human prostate tumor
xenografts was chosen for these studies because it
constitutes a renewable, largely characterized
source of human prostate tumor tissue (Ellis et al.,
1996; Williams et al., 1997; Linja et al., 2001; Corey
et al., 2002; Laitinen et al., 2002; True et al., 2002).
The xenografts were maintained by serial passage
in intact athymic Balbc nu/nu male mice and were
harvested at passage 45 for LuCaP 23.1, 40 for
LuCaP 23.8, 25 for LuCap 23.12, 67 for LuCaP 35,
17 for LuCaP 41, 22 for LuCaP 49, and 19 for
LuCaP 58. At sacrifice, tumor samples were har-
vested and frozen in optimum cutting temperature
medium.
Alleleotyping
PCR was used for amplification of sequences
containing highly polymorphic microsatellite re-
peat markers at loci of interest on chromosome 8
(12 sequences). The cytogenetic and map position
for each locus was obtained from the UCSC Ge-
nome Bioinformatics database (http://genome.cse.
ucsc.edu/). Primer sequences were obtained from
public databases maintained by the National Cen-
ter for Biotechnology Information (http://www.
ncbi.nlm.nih.gov/), as accessed through the Inter-
net. DNA was prepared from frozen xenograft tis-
sues, and PCR reactions were performed as previ-
ously described (Prasad et al., 1998). Allelic dosage
was scored as “1” if a single band was observed in
the PCR reaction or as “2” if two discrete bands
were observed.
RNA Profiling by cDNA Microarray
RNA was prepared from normal benign prostatic
and xenograft tissues after homogenization and ly-
sis in Trizol reagent (Invitrogen Life Technolo-
gies, Carlsbad, CA) following the manufacturer’s
instructions. The RNA was further purified by use
of RNeasy reagents (Qiagen, Valencia, CA), and 20
g of total RNA from each sample was labeled with
Cy5 fluorescent dye by use of a CyScribe first-
strand cDNA labeling kit. For each experiment, 20
g of Universal Human Reference RNA (Strat-
agene, La Jolla, CA) was labeled with Cy3 by use of
similar protocols. After purification on AutoSeq
G50 columns (Amersham Biosciences, Piscataway,
NJ), the labeled probes were combined, dried
down to 5 l, and added to 45 l SlideHyb #1
hybridization buffer (Ambion, Houston, TX), pre-
warmed to 68°C. The probe/hybridization mixture
was pre-incubated at 68°C for 5 min, then trans-
ferred to the cDNA microarray slide, which was
coverslipped and incubated in a moist chamber at
45°C for 16 hr. The slides were washed for 10 min
each in 2 SSC, 0.2% SDS at 45°C, 2 SSC at
room temperature, and 0.2 SSC at room temper-
ature; rinsed; dried; and evaluated with a GenePix
4000A Axon laser scanner and associated software
(Axon Instruments, Burlingame, CA).
Chromosome 8 cDNA Array
The custom chromosome 8 array was produced
at the University of Michigan Comprehensive Can-
cer Center cDNA and Affymetrix Microarray Core.
This array consisted of PCR products amplified
from 677 Research Genetics (Huntsville, AL) hu-
man cDNA clones whose sequences mapped to
chromosome 8. To identify these clones, our lab-
oratory annotated the GenBank accession num-
bers associated with all 25,921 Research Genetics
human cDNA clones with chromosomal location
by use of information from the National Center
for Biotechnology Information Ensembl database
(http://www.ensembl.org/homo_sapiens) and the
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UCSC Genome Bioinformatics database (http://
genome.cse.ucsc.edu/). According to information in
these databases, 677 clones contained sequences
mapping to human chromosome 8; 259 mapped to
8p and 418 mapped to 8q. A complete list of
cDNAs spotted onto the chromosome 8 array can
be obtained at http://www-personal.umich.edu/
jcoska/Chrom8Array.xls.
Northern Blot Analysis
A 20-g sample of total RNA from each speci-
men isolated as described above was resolved on
1% formaldehyde agarose gels and transferred to a
Nytran membrane by use of a TurboBlotter appa-
ratus (Schleicher & Schuell, Keene, NH). Each
blot was probed with radiolabeled PCR products
amplified for the gene of interest, hybridized by
use of the ExpressHyb Hybridization Solution
(Clontech, Palo Alto, CA), and visualized on X-
OMAT film (Kodak, Rochester, NY).
Statistical Analysis
Data used for this study were background-sub-
tracted median intensity values with average log
intensities greater than 8. Data from each array
were normalized to remove dye-bias by use of a
rank-invariant normalization method (Tseng et al.,
2001). This normalization method attempts to find
genes that do not appear to be differentially ex-
pressed in the two samples hybridized to a microar-
ray. A non-linear regression (lowess) line was then
fitted to these points and used for normalizing the
data. Before making comparisons between arrays,
we performed a quantile normalization of the rank-
invariant normalized array data. We assumed that
the distribution of the array data was the same for
all arrays, but that the scale of the data may be
quite different. To correct for this difference in
scale, we used data from one array as baseline and
adjusted all other arrays to match (Shedden,
2002a,b). Differentially expressed genes were de-
tected with SAM (significance analysis of microar-
rays) (Tusher et al., 2001). Hierarchical clustering
was used for grouping of genes with similar expres-
sion patterns (Eisen et al., 1998).
RESULTS
Allelotyping
Allelotyping experiments showed that LuCaPs
23.1, 49, and 58 demonstrated one allele for all
twelve 8p loci examined, suggesting that one copy
of the entire short arm of chromosome 8 was de-
leted in those specimens. LuCaP 23.8 also demon-
strated extensive deletion for one copy of 8p, al-
though the results were inconclusive for the most
proximal locus, D8S255, thus precluding an assess-
ment of complete deletion. LuCaP 23.12 demon-
strated one allele for 10 loci extending from
D8S504 to D8S87 and two alleles at locus D8S1121,
suggesting that the most proximal portion of 8p was
retained in that xenograft. LuCaPs 35 (loci
D8S504-NEFL) and 41 (loci D8S504-D8S540) dem-
onstrated deletion for one copy of distal 8p with
retention of two copies of proximal 8p sequences
(Table 1). Taken together, the allelotyping data
demonstrated deletion for one copy of the entire 8p
chromosomal region for all xenografts except Lu-
CaPs 35 and 41, which were deleted for one copy of
the distal 8p region only. These results were con-
sistent with those obtained by others who used
FISH and comparative genome hybridization
(CGH), except that LuCaP 35 evinced loss of distal
8p by allelotyping but not by CGH analysis, and
LuCaP 41 demonstrated loss of all of one copy of
the entire 8p arm by CGH analysis but not by
allelotyping (Williams et al., 1997; Laitinen et al.,
2002). In addition, FISH and CGH analyses dem-
onstrated gain of one copy of 8q in LuCaPs 23.8,
23.12, 35, and 58, and amplification of 8cen-q21
and 8q24-qter in LuCap 23.8, 8q21–q22 in LuCaP
35, and 8q23-qter in LuCaP 58 (Williams et al.,
1997; Laitinen et al., 2002).
cDNA Microarray Analysis
The xenograft tissues were transcriptionally pro-
filed for coding sequences mapping to chromosome
8. To accomplish this, we constructed a chromo-
some 8 array by use of PCR products amplified
from 677 clones from the Research Genetics hu-
man cDNA library whose sequences mapped to
chromosome 8. The chromosome 8 sequence spec-
ificity and the exact physical location of each tran-
script on chromosome 8 were established by anno-
tation of the cloned sequences with chromosome
mapping information derived from the National
Center for Biotechnology Information Ensembl
database (http://www.ensembl.org/homo_sapiens)
and the UCSC Genome Bioinformatics database
(http://genome.cse.ucsc.edu/).
Five specimens of histologically verified nor-
mal benign human prostate tissues obtained after
radical prostatectomy from patients diagnosed
with prostate cancer were used as controls. The
five normal benign prostate tissues and LuCaP
tumors 23.1, 23.12, 23.8, 35, 41, 49, and 58 were
analyzed for the gene expression pattern of tran-
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scripts mapping to chromosome 8 by use of a
custom chromosome 8 array. Because the intent
in these studies was to determine whether a
common set of genes were transcriptionally
down-regulated in tissues deleted for one copy of
8p, the xenograft data were considered together
rather than separately. After background subtrac-
tion and quantile normalization of the rank-in-
variant normalized array data, differentially ex-
pressed genes were detected by use of SAM
(Tusher et al., 2001; Shedden, 2002a,b).
Hierarchical clustering was used to group tissues
and genes with similar expression patterns (Eisen
et al., 1998). As expected, the five normal tissues
clustered together, as did the seven xenograft tis-
sues (Fig. 1). Of the three xenografts originally



























































































































































































































































































Figure 1. Hierarchical clustering of differentially expressed genes
mapping to 8p. Normal human prostate tissues cluster together on the
left; malignant human prostate tissues cluster together on the right of
the diagram. Genes are identified by GenBank accession number and
are arranged by chromosomal position, from 8pter (top) to 8p11
(bottom). Green boxes indicate statistically significant transcriptional
down-regulation in tumors compared to normal specimens; red indi-
cates up-regulation, and black indicates that expression was not statis-
tically significant for that specimen; 28/33 differentially expressed genes
are down-regulated in the tumor specimens compared to the normal
prostate specimens.
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from the same patient (LuCaPs 23.1, 23.8, and
23.12), LuCaPs 23.1 and 23.12 clustered together,
whereas LuCaP 23.8 clustered with LuCaP 35.
Interestingly, LuCaPs 23.1 and 23.12 were both
characterized by gain of the entire 8q chromosomal
arm, whereas LuCaPs 23.8 and 35 were distin-
guished by gain of 8q and amplification of discrete
regions on 8q (Williams et al., 1997; Laitinen et al.,
2002).
Statistical analysis demonstrated that the mean
expression of 88/677 (13%) genes spotted onto the
array was statistically significantly different in pros-
tate tumor xenografts compared to normal prostate
tissues. Of the 88 differentially expressed genes, 33
mapped to 8p and 55 to 8q. Twenty-eight of 33
(85%) of the differentially expressed genes that
mapped to 8p were down-regulated in the prostate
tumor xenografts compared to normal prostate tis-
sues. These results are consistent with the expec-
tation that a majority of genes mapping to 8p would
be transcriptionally down-regulated in the prostate
tumor xenografts, which are deleted for one copy of
8p. The five gene sequences that constitute the
exceptions to this trend encode two ESTs (Gen-
Bank H95956, R07012), two hypothetical proteins
(GenBank AA056538, AA678348), and the ATIP1
gene (GenBank AA496896). Interestingly, three
genes previously identified as tumor-suppressor
genes mapping to 8p (NKX3.1, LZTS1, and MSR1)
were transcriptionally down-regulated in a subset
of the 8p-deleted xenografts but did not achieve
significance by SAM analysis. NKX3.1 was down-
regulated in LuCaPs 35 and 49, MSR1 was down-
regulated in LuCaPs 41 and 49, and LZTS1 was
down-regulated in LuCaPs 23.1, 23.12, 49, and 58.
The expression pattern on 8q was more com-
plex, with 23 genes (42%) up-regulated and 32
genes (58%) down-regulated in the prostate tumor
xenografts compared to normal prostate tissues.
There were no obvious correlations between gene
expression level and 8q copy number in the pros-
tate tumor xenografts, although the proportion of
up-regulated genes was significantly higher on the
q arm than on the p arm (P  0.017). The identities
of the differentially expressed genes mapping to 8p
are listed in Table 2. The observation of transcrip-
tional down-regulation for the majority of differen-
tially expressed genes mapping to 8p in the xeno-
grafts compared to normal prostate tissues is
consistent with the allelotyping data demonstrating
loss of all or part of one copy of 8p in the seven
xenografts (Table 1 and Fig. 1).
Validation of cDNA Microarray Data
We conducted Northern blot analysis to deter-
mine whether the gene expression profiles ac-
quired from the cDNA microarray data were accu-
rate. Two transcripts originating from genes
mapping to the proximal 8p region were chosen for
the validation studies, RBP-MS and TEM5.
RBP-MS was chosen in particular because PCR
products from two different cDNA clones repre-
senting this sequence were spotted onto the array,
and expression data acquired from both spots were
consistent with transcriptional down-regulation of
RBP-MS in the xenografts (Table 2). The same
Northern blot filter was sequentially hybridized to
radiolabeled probes for RBP-MS, TEM5, and
GAPDH (as a loading control) and demonstrated
expression of all three genes in three of the same
normal human prostate tissues previously analyzed
by cDNA microarray (N4, N5, and N6) (Fig. 2).
However, both RBP-MS and TEM5 were not ex-
pressed in LuCaPs 49, 23.1, and 41, whereas
GAPDH was abundantly expressed in all three
prostate tumor xenograft tissues (Fig. 2). These
results were consistent with the cDNA microarray
results and demonstrated ablation of TEM5 and
RBP-MS gene expression in prostate tumor xeno-
grafts deleted for one copy of 8p.
DISCUSSION
These studies were intended to determine
whether gene dosage correlated with gene expres-
sion level in human prostate tumors with known
structural and numerical alterations involving chro-
mosome 8. The xenograft tissues were particularly
suited to these studies because they provided a
renewable source of prostate tumor tissue with
known 8p deletions that could be extensively char-
acterized by RNA profiling. Prostate cancer cell
lines could also have been examined, but proved to
be unsuitable because they were far less “uniform”
in their chromosome 8 composition, and it was
unclear whether some cell lines demonstrated de-
letion in addition to translocation of 8p sequences.
For example, LNCaP cells have four copies of
chromosome 8; DU145 exhibits a der(7;8)(p10;q10)
translocation; and PC3 exhibits del(8)p21, der(8)
t(X;8)(q10;q10), and der(8)t(8;15)(q10;10) chromo-
somes (Beheshti et al., 2000). The 22Rv1 cell line
actually demonstrates gain for a portion of 8p, in-
cluding 8p12–p22 (Laitinen et al., 2002). There-
fore, we chose to profile the LuCaP series of hu-
man prostate tumor xenografts with known 8p
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deletions and five normal human prostate tissues
diploid for 8p as controls.
In this study, we hypothesized that gene expres-
sion levels would be reduced or ablated in tumors
deleted, or haploinsufficient, for one copy of 8p.
Consistent with this hypothesis, 28/33 (85%) of the
differentially expressed genes that mapped to 8p
were down-regulated in the prostate tumor xeno-
grafts compared to normal prostate tissues.
Two of the genes identified as transcriptionally
down-regulated in xenografts deleted for 8p were
TEM5 and RBP-MS. TEM5 maps to 8p12 and en-
codes a seven-pass transmembrane protein (Car-
son-Walter et al., 2001). Although the protein was
originally described as exclusively expressed on the
surface of tumor endothelial cells, our studies show
that the TEM5 gene transcript was clearly ex-
pressed in normal, but not malignant, prostate ep-
ithelium. RBP-MS maps to 8p21 at the distal
boundary of the 8p21–8p12 deletion breakpoint
previously observed in human prostate tumors
(Shimamoto et al., 1996; Prasad et al., 1998). The
RBP-MS gene encodes an RNA-binding protein
with complex alternative splicing patterns, result-
ing in at least 12 different transcripts (Shimamoto
et al., 1996). The original description of this gene
also showed strong expression of RBP-MS tran-
scripts in the human prostate, as well as the heart,
small and large intestines, and ovaries (Shimamoto
et al., 1996). The more conserved N-terminal re-
gion contains RNA-binding sequences homologous
to similar motifs in the Drosophila couch potato gene
transcript, whereas the COOH-terminal region is
highly divergent between the splice variants. Re-
cent studies demonstrated that couch potato is in-
volved in peripheral nervous system development,
but is also highly expressed in the ring gland, the
major Drosophila endocrine organ, throughout de-
velopment (Harvie et al., 1998). The presence of
RNA-binding motifs suggests that the RBP-MS










ESTs AA701521 2.488 131657 Down 8p23
KIAA0711 AA702544 1.912 1633119 Down 8p23
ESTs R59116 1.948 2434358 Down 8p23
FLJ11210 AA056538 3.402 7055704 Up 8p23
DKFZp434D2426 AA703117 3.237 9116035 Down 8p23
TNKS AA939231 2.135 9721956 Down 8p23
ESTs AA007596 1.977 12496945 Down 8p23
ZDHHC2 AA461174 2.511 17416305 Down 8p22
FLJ32642 AA397919 1.901 17488997 Down 8p22
ATIP1 AA496896 2.580 17837267 Up 8p22
ESTs AA621202 2.644 17846673 Down 8p22
FGL1 AA677287 2.785 18045902 Down 8p22
PCM1 N47957 1.943 18132400 Down 8p22
ASAH1 AA664155 2.384 18234223 Down 8p22
SCAM-1 AA700222 4.063 22724596 Down 8p22
TNFRSF10B AA453410 2.201 23264878 Down 8p21
STC1 AA126561 2.717 24085387 Down 8p21
FLJ25804 AA678348 2.532 25792008 Up 8p21
ESTs N51117 3.448 27265764 Down 8p21
ESTs H95956 2.756 29620387 Up 8p21
DUSP4 AA444049 2.003 29960552 Down 8p21
RBPMS R66067 2.823 30220588 Down 8p21
RBPMS W67323 2.871 30870731 Down 8p21
PPP2CB AA490696 2.129 31553844 Down 8p21
GSR AA777289 2.333 31641629 Down 8p21
NRG1 H24357 1.848 33227982 Down 8p12
TEM5 AA044447 3.954 36112103 Down 8p12
STAR AA679454 2.335 38871582 Down 8p12
C8orf4 H16793 2.726 40119560 Down 8p12
POLB R44427 2.926 42052597 Down 8p12
IKBKB N94412 1.969 42092090 Down 8p12
PLAT R38933 2.076 42273247 Down 8p12
ESTs R07012 2.481 48374593 Up 8p11
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protein may be involved in RNA processing, trans-
port, stabilization, or translation. Moreover, its high
expression levels in the major endocrine organs of
Drosophila (ring gland) and humans (ovaries, pros-
tate) suggests that the RBP-MS protein may play a
major role in these processes during sexual matu-
rity and/or reproduction.
Several recent studies have suggested that hap-
loinsufficiency for specific genes is associated with
the initiation or progression of sporadic tumors in
mice and humans. In particular, haploinsufficiency
attributed to chromosomal deletion rather than
base sequence mutation associated with tumori-
genesis and progression has been described for the
PTEN gene in mouse prostate tumors, the p27KIP1
gene in human acute lymphocytic leukemia, and
the KLF5 transcription factor gene in human breast
tumors (Komuro et al., 1999; Kwabi-Addo et al.,
2001; Chen et al., 2002). Taken together, these
data suggest that the transcriptional down-regula-
tion of genes associated with deletion-induced hap-
loinsufficiency may help identify candidate tumor-
suppressor genes in human cancers. In particular,
our finding that haploinsufficiency and transcrip-
tional down-regulation for genes mapping to 8p are
largely coincident in human prostate tumors pro-
vides a powerful tool for the identification of tu-
mor-suppressor genes associated with human pros-
tate cancer initiation and progression.
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